Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices
The New York Times - Science •
In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it.
